Aptorum Group

Update in progress

APM (NGM)

Aptorum Group Limited is a clinical-stage biopharmaceutical company that discovers, develops, and aims to commercialize therapies for cancer and infectious diseases. Its pipeline includes SACT-1, in phase 1 for neuroblastoma and other cancers; SACT-2 and SACT-3; ALS-4, in phase 1 for bacterial infections such as S. aureus, TB, and Pseudomonas; SACT-COV19 in preclinical development; and ALS-1, ALS-2/3 in preclinical stages. Formerly APTUS Holdings Limited, renamed in 2017. Founded 2010, headquartered in London.